SRDX - Surmodics, Inc.
| Previous Close | 56.41 |
| Open | 56.73 |
| Bid | 47.38 x 800 |
| Ask | 199,999.98 x 900 |
| Day's Range | 55.82 - 57.05 |
| 52 Week Range | 26.90 - 82.35 |
| Volume | 68,549 |
| Avg. Volume | 96,545 |
| Market Cap | 764.312M |
| Beta (3Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.13 |
| Earnings Date | Nov 14, 2017 - Nov 20, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.00 |
- Zacks•yesterday
Here's Why Investors Should Hold DaVita (DVA) Stock Now
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
- Zacks•2 days ago
Medidata's (MDSO) Margins Under Pressure, Competition Rife
Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.
- Zacks•4 days ago
Will Surmodics Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Surmodics.
- Zacks•4 days ago
Here's Why Investors Should Buy Surmodics (SRDX) Stock Now
Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.
- Business Wire•5 days ago
Surmodics Announces Appointment of Timothy J. Arens as Chief Financial Officer
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced the appointment of Timothy J. Arens, Vice President of Corporate Development and Strategy, as the company’s new Chief Financial Officer (CFO), effective immediately. Arens was named interim CFO in May 2018 following the departure of Andrew LaFrence. Arens’ corporate development and strategy responsibilities will be absorbed into his CFO role.
- Zacks•9 days ago
Baxter's Acute Therapies Profile Strong, Competition Rife
Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.
- Zacks•10 days ago
Here's Why Investors Should Retain AmerisourceBergen Stock
AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.
- Zacks•12 days ago
Here's Why You Should Buy Wright Medical (WMGI) Stock Now
A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.
- Zacks•15 days ago
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.
- Simply Wall St.•16 days ago
Should You Worry About Surmodics, Inc.’s (NASDAQ:SRDX) CEO Salary Level?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2010 Gary Maharaj was appointed CEORead More...
- Zacks•17 days ago
Here's Why You Should Invest in McKesson (MCK) Stock Now
McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.
- Zacks•18 days ago
QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.
- Business Wire•18 days ago
Surmodics to Host Virtual Annual Meeting of Shareholders
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 13, at 4 p.m. CT (5:00 p.m. ET), as a virtual meeting. Gary Maharaj, chief executive officer, and Sue Knight, chair of the board, will provide a brief update on business and key strategic initiatives underway at the Company.
- Zacks•19 days ago
Here's Why You Should Hold Intuitive Surgical (ISRG) Stock
Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.
- Thomson Reuters StreetEvents•22 days ago
Edited Transcript of SRDX earnings conference call or presentation 30-Jan-19 10:00pm GMT
Q1 2019 Surmodics Inc Earnings Call
- Zacks•22 days ago
IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View
IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.
- Zacks•22 days ago
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet
Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.
- Zacks•22 days ago
ABIOMED (ABMD) Q3 Earnings Beat, Impella Maintains Momentum
ABIOMED's (ABMD) flagship Impella sees a solid Q3; fiscal 2019 outlook raised.
- Zacks•23 days ago
Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid
Surmodics' (SRDX) fiscal Q1 sees solid contributions from all segments.
- Zacks•23 days ago
AmerisourceBergen (ABC) Beats on Q1 Earnings, Trims EPS View
AmerisourceBergen (ABC) registers solid growth at the Pharmaceutical Distribution segment and the World Courier business in first-quarter fiscal 2019.
- Zacks•23 days ago
Baxter's (BAX) Earnings, Revenues Beat Estimates in Q4
Baxter (BAX) gains from the Renal Care and Advanced Surgery units in fourth-quarter 2018; Clinical Nutrition revenues soft.
- Benzinga•23 days ago
The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 30) Varian Medical Systems, Inc. (NYSE: VAR ) EXACT Sciences ...
Motley Fool•24 days agoSurmodics Inc (SRDX) Q1 2019 Earnings Conference Call Transcript
SRDX earnings call for the period ending December 31, 2018.
- Zacks•24 days ago
SurModics (SRDX) Tops Q1 Earnings and Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of 1300.00% and 17.68%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•24 days ago
SurModics: Fiscal 1Q Earnings Snapshot
On a per-share basis, the Eden Prairie, Minnesota-based company said it had net income of 9 cents. Earnings, adjusted for one-time gains and costs, came to 12 cents per share. The drug delivery technology ...
